Previous 10 | Next 10 |
IVERIC bio (NASDAQ:ISEE) is scheduled to announce Q3 earnings results on Tuesday, November 9th, before market open. The consensus EPS Estimate is -$0.26. Recently, the company priced its upsized public offering of 9M shares of common stock at $16.75/share with expected gross proceed...
ADT,AGEN,AGTC,ALLT,APRN,AUD,OTCPK:BAYZF,BHVN,BNTX,BSY,CAH,CANO,CCO,CEVA,CNCE,CORR,DCTH,DHI,DRNA,EBIX,ECOM,EGRX,EPZM,EXK,FOLD,GILT,GLNG,GOL,HAE,HAIN,HGV,HUYA,IGT,IIVI,INSW,ISEE,ITCI,KNDI,KPLT,MIDD,MLCO,MNTV,MRNS,MRSN,MSGE,OTCPK:NSANY,NSPR,NUWE,OCGN,OESX,OSG,OWL,PLTR,PRPL,PRTY,QTNT,SATS,SEAS,SE...
IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in a fireside chat at the Credit Suisse 30 th Annual Virtual Healthcare Conference on Tuesday, November 9, 2021 at 11:20 a.m....
IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2021 financial and operating results on Tuesday, November 9, 2021. Following the announcement, the Iveric Bio management team will host a live conference call and webcast at 8:00 a.m. Eastern Time ...
IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced the pricing of an upsized underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $16.75 per share, less underwriting discounts and commissions. In addition, in connec...
IVERIC bio, Inc. (Nasdaq: ISEE) (the “Company”), today announced that it is commencing an underwritten public offering of $125.0 million of shares of its common stock. In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase ...
Shares of IVERIC bio Inc. (NASDAQ:ISEE) traded today at $18.08, eclipsing its 52-week high. This new high was reached on above average trading volume as 13.6 million shares traded hands, while the average 30-day volume is approximately 9.1 million shares. IVERIC bio Inc is a biopharmaceu...
Gainers: Viracta Therapeutics (NASDAQ:VIRX) +5%. Angi (NASDAQ:ANGI) +4%. Calithera Biosciences CALA +3%. Progenity (NASDAQ:PROG) +2%. IVERIC bio (NASDAQ:ISEE) +2%. Losers: TaskUs TASK -8%. DLocal Limited (NASDAQ:DLO) -7%. EverQuote EVER -6%. TORM plc (NASDAQ:TRMD) -4%. Lim...
IVERIC bio Inc. (NASDAQ:ISEE) traded at a new 52-week high today of $17.07. This new high was reached on above average trading volume as 13.6 million shares traded hands, while the average 30-day volume is approximately 8.8 million shares. Over the past year, IVERIC bio Inc. has traded i...
Iveric Bio is developing Zimura - indicated for Geographic Atrophy - an eye disease that often leads to blindness. Zimura has met its primary endpoint in a pivotal Phase 3 trial, and data from a fully enrolled second Phase 3 will be available in H222. Zimura's chief rival Pegcetac...
News, Short Squeeze, Breakout and More Instantly...
Astellas Completes Acquisition of Iveric Bio PR Newswire TOKYO and PARSIPPANY, N.J. , July 11, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that it has successfully completed the acquisit...
Shares of IVERIC bio, Inc. (NASDAQ: ISEE) traded at a new 52-week high today and are currently trading at $39.73. So far today, approximately 1.78M shares have been exchanged, as compared to an average 30-day volume of 5.04M shares. IVERIC bio, Inc., a biopharmaceutical company, discovers and...
IVERIC bio, Inc. (NASDAQ: ISEE) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 1.93% on the day to $38.77. IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal disease...